Seeking Alpha

XBiotech nabs new patent in Canada

|About: XBiotech Inc. (XBIT)|By:, SA News Editor

The Canadian Patent Office has granted XBiotech (NASDAQ:XBIT) a Patent Number 56003542-6CA covering the use of bermekimab in the treatment of inflammatory skin diseases.

XBiotech has conducted a number of clinical trials in dermatology using bermekimab, including studies in hidradenitis suppurativa, atopic dermatitis, and psoriasis vulgaris (plaque psoriasis).

The company has also published clinical findings for the treatment of psoriasis and acne.

Subscribe for full text news in your inbox